Brief: FDA Issues Approvable Letter For Nyxoah's Genio® System
March 26 (Reuters) - Nyxoah SA NYXH.BR: FDA ISSUES NYXOAH AN APPROVABLE LETTER FOR ITS GENIO® SYSTEM DECISION DOES NOT IMPACT GENIO'S CE MARK OR ONGOING COMMERCIAL ACTIVITIES IN EUROPE Source text: ID:nGNEbr7Wy9 Further company coverage: NYXH.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Nyxoah SA
See all newsBelgium's Nyxoah Q3 revenue rises on US commercialization
Brief: Nyxoah SA Q3 Gross Profit EUR 5.785 Million
Brief: Nyxoah SA Submits Pma Supplement To FDA To Expand Genio Indication To Complete Concentric Collapse Patients
Brief: Nyxoah Says Co Appoints Liam Kelly As Chief Executive Officer Effective October 1
Brief: Cvrx Appoints John Landry As Chief Financial Officer